Bukwang Pharmaceutical Acquires 60 Million Shares of Union Korea Pharm via Third-Party Allotment, Securing 75.14% Stake, Diluting Existing Shareholders

Bukwang Pharmaceutical acquired 60 million common shares of Union Korea Pharm at 500 KRW per share through a third-party allotment on May 28, 2026, following court approval of the rehabilitation plan, increasing its stake to 75.14%.
With Union Korea Pharm's total outstanding shares at 79,854,006, the new shares represent 75.14% of the total, causing significant dilution for existing minority shareholders.
The capital injection is aimed at supporting the company's rehabilitation, focusing on operational normalization rather than short-term profitability, with Bukwang's increased financial burden and subsequent governance stability being key factors for future stock price outlook.
[AI Summary]Bukwang's acquisition of a 75.14% stake in Union Korea Pharm via a rehabilitation plan unavoidably dilutes existing shareholders. The low acquisition price of 500 KRW per share reflects no control premium, and uncertainty remains regarding operational turnaround. Short-term downside pressure and medium-to-long-term rehabilitation success are core investment risks.